The Dexcom ONE real-time Continuous Glucose Monitoring (rt-CGM) System is now available to be prescribed across the United Kingdom.
The decision follows new guidelines from the National Institute for Health and Care Excellence (NICE) which recommends adults with type 1 diabetes should be offered a choice of glucose sensor, children should be offered rt-CGM and people with type 2 diabetes using insulin can be considered for rt-CGM as an alternative to their current sensor.
Dexcom ONE is part of a range of CGM systems offered by the company for people with diabetes in the UK that also includes the Dexcom G6 and the upcoming Dexcom G7. With the new portfolio of products, Dexcom meets the criteria set out by NICE.
According to the National Health Service specialty adviser for diabetes, Professor Partha Kar: “The next step in the evolution of type 1 diabetes technology continues to unfold and at NHS England, we are thrilled to be part of the solution. With Dexcom ONE on prescription, more people will have access to potentially life changing CGM technology, leading to better health outcomes and more choice for people with diabetes.”
● Continuous glucose monitoring (CGM) and flash glucose monitoring (Flash) are two methods that people with diabetes use to track their blood glucose levels day and night. CGM devices transmit data wirelessly to a reader or smartphone. Flash sensors must be scanned with a handheld reader or smartphone.
Advocacy Action: Can you use the NICE guidance to help the case for reimbursement in your country? https://www.nice.org.uk/guidance/ng17